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Summary
Objective Growth hormone (GH)/insulin-like growth factor
(IGF) axis and insulin are key determinants of bone remodel-
ling. Homozygous mutations in the GH-releasing hormone
receptor (GHRHR) gene (GHRHR) are a frequent cause of
genetic isolated GH deficiency (IGHD). Heterozygosity for
GHRHR mutation causes changes in body composition and
possibly an increase in insulin sensitivity, but its effects on bone
quality are still unknown. The objective of this study was to
assess the bone quality and metabolism and its correlation with
insulin sensitivity in subjects heterozygous for a null mutation
in the GHRHR.
Patients and methods A cross-sectional study was performed
on 76 normal subjects (68Æ4% females) (N/N) and 64 individuals
(64Æ1% females) heterozygous for a mutation in the GHRHR
(MUT/N). Anthropometric features, quantitative ultrasound
(QUS) of the heel, bone markers [osteocalcin (OC) and Cross-
Laps], IGF-I, glucose and insulin were measured, and homeosta-
sis model assessment of insulin resistance (HOMAIR) was
calculated.
Results There were no differences in age or height between
the two groups, but weight (P = 0Æ007) and BMI (P = 0Æ001)
were lower in MUT/N. There were no differences in serum
levels of IGF-I, glucose, T-score or absolute values of stiffness
and OC, but insulin (P = 0Æ01), HOMAIR (P = 0Æ01) and
CrossLaps (P = 0Æ01) were lower in MUT/N. There was no
correlation between OC and glucose, OC and HOMAIR in the
140 individuals as a whole or in the separate MUT/N or N/N
groups.
Conclusions This study suggests that one allele mutation in the
GHRHR gene has a greater impact on energy metabolism than on
bone quality.
(Received 21 July 2011; returned for revision 15 August 2011;
finally revised 7 October 2011; accepted 7 October 2011)
Introduction
Bone mass is influenced by several factors including body composi-
tion, bone remodelling activity, insulin sensitivity and growth
hormone (GH)/insulin-like growth factor I (IGF-I) secretion.1–8
Previous studies have shown that acquired GH deficiency (GHD)
associated with multiple pituitary deficits is linked to low bone
mineral density (BMD) and increased fracture risk compared with
the general population.9 The incidence of isolated GH deficiency
(IGHD) is estimated to be 1 of 3480 to 1 of 10 000 live births.10
Albeit rare, homozygous mutations in the GH-releasing hormone
receptor (GHRHR) gene represents a exceptional clinical model
for the investigation of GHD and its consequences in human
health.11 On the other hand, the prevalence of heterozygous carri-
ers in the normal population is unknown. As the major determi-
nants of peak bone mass and strength are genetic, it would be
worthwhile to determine whether this genetic trait can cause lower
bone quality.
We have identified large kindred of patients with familial IGHD,
with 105 affected individuals over eight generations, residing in
Itabaianinha County, in the Northeastern Brazilian state of Sergipe.
IGHD is caused by a homozygous mutation in the splice donor site
of intron 1 (c.104+1G>A) of the GHRHR gene.12 Adult IGHD
individuals present severely short stature, reduction in lean mass
and increase in per cent fat mass,13,14 They have normal IGF-bind-
ing protein 1 and 215 and leptin,14 high adiponectin levels14 and
obvious reduction in serum IGF-I, IGF-II, IGF-binding protein 315
and insulin.13,14 They also have a reduced T-score of bone stiffness,
assessed by heel quantitative ultrasound (QUS), when compared to
age-matched normal controls.16
We have recently reported that heterozygous carriers of this
mutation have a phenotype that includes changes in body compo-
sition but not in serum IGF-I or stature.17 The aim of this study
was to extend the study of heterozygous carriers to their bone
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phenotype, by assessing bone quality and biochemical markers of
bone formation and resorption.
Subjects andmethods
Subjects
The study comprised adult individuals with normal stature, aged
25–75 years from the Itabaianinha community who were first-,
second- or third-degree relatives of IGHD individuals, recruited by
advertisement on a local bulletin board and by word of mouth. We
collected buccal cells from 240 adult individuals, and DNA was
extracted by alkaline lysis. Genotyping for the c.104+1G>A muta-
tion was carried out as previously described.17 Subjects with a his-
tory of childhood disease known to influence bone density such as
hepatic or renal failure or with a history of exposure to chronic ste-
roids, medications for the treatment of osteoporosis, anticonvul-
sants, any use of alcohol and tobacco (current or previous),
physical inactivity (bedridden or walking difficulties) and vigorous
physical activity (athletes) were excluded. We identified 76 subjects
heterozygous for the c.104+1G>A GHRHR mutation (MUT/N)
and 77 sex-matched genotype-proven normal subjects (N/N), as
previously reported.17 Twelve MUT/N subjects and one individual
in the N/N group were excluded because of the lack of data regard-
ing one or more variables of the protocol. Therefore, 64 MUT/N
(64Æ1% female) and 75 N/N (68Æ4% female) individuals were
included in the study. The protocol was approved by the Johns
Hopkins University, CONEP and the Federal University of Sergipe
Ethics Committees. All subjects gave written informed consent.
Height (m) and body weight (kg) were measured with a portable
stadiometer and a portable scale. Body mass index (BMI) was
calculated using the formula: weight in kg/height m2.
Laboratory assessment
Insulin-like growth factor-I was measured in duplicate by DSL-
5600 immunoradiometric assay (IRMA; Diagnostic Systems Labo-
ratories, Webster, TX, USA). To pool IGF-I measurements in both
genders and in different ages, results were normalized by standard
deviation scores (SDS). SDS for serum IGF-I was calculated by
subtracting the mean IGF-I level for age from the individual value
and dividing this value by the standard deviation of the respective
mean age given by the manufacturer. The normal SDS distribution
has a mean of 0 and a standard deviation of ±1. Values of SDS
above +2 or below )2 are by definition abnormal. Glucose was
measured by Accu-Check Advantage (Roche, San Francisco, CA,
USA). Serum levels of insulin was measured by a solid-phase,
two-site chemiluminescent assay DPC-5210 (Diagnostic Products
Corporation, Los Angeles, CA, USA), and insulin resistance was
estimated using the homeostasis model assessment of insulin resis-
tance (HOMAIR) with the formula: fasting serum insulin (lU/
ml) · fasting plasma glucose (mmol/l)/22Æ5.18 IGF-I and insulin
assays were performed at the hormone laboratory of the University
Hospital, Federal University of Sergipe. Osteocalcin (OC) was mea-
sured by DSL-7600 IRMA (Diagnostic Systems Laboratories, Inc.,
Webster, TX, USA), and serum levels of the C-terminal cross-link-
ing telopeptide of type I collagen (CrossLaps) were measured by
DK-2730 ELISA IRMA (Orion Diagnostica, Webster, TX, USA) in
the Metabolism Laboratory of the General Hospital, School of
Medicine of Ribeira˜o Preto, University of Sa˜o Paulo. The intra-
assay coefficients of variation (CVs) for the determination of IGF-I,
insulin, OC and CrossLaps were 6Æ5%, 4Æ2%, 8Æ3% and 7Æ2%,
respectively. All the assays were performed in a single run.
Bone status measurements
We determined the bone stiffness index by heel QUS. QUS is a
water-based system that uses transmission of an ultrasound wave
in a temperature-controlled water bath (37 C) through the heel.
This measurement was performed with rigorous standardization of
subject positioning using the Achilles Insight device (Lunar/GE,
Madison, WI, USA). QUS measures the stiffness index by the equa-
tion: stiffness = (0Æ67 · coefficient of ultrasound broadband atten-
uation in dB/MHz + 0Æ28 · speed of sound in m/s) ) 420. Bone
stiffness was expressed as the percentage of the values obtained by
the manufacturer for a young adult population. For the determined
bone stiffness index, we chose a normal South American popula-
tion. The CV of bone stiffness measurement was 2Æ23%.
Statistical analysis
Values for continuous variables were expressed as mean ± stan-
dard deviation. Physical characteristics (weight, height and BMI),
were analysed by the Student t-test. Insulin and HOMAIR data were
transformed into decimal logarithm before analysis. A general
linear model, encompassing both analysis of variance (anova) and
regression, using HOMAIR as a dependent variable and anova with
two factors (sex and group) adjusted for age and BMI was subse-
quently used. The regression model was used to examine possible
associations between weight and BMI with bone markers, and
between bone markers with glucose, insulin and HOMAIR, by esti-
mating their square R (R2). To test the hypothesis of any correla-
tion between OC and glucose, insulin and HOMAIR, we used
Spearman¢s rank correlation. The Pearson correlation coefficient
was used to analyse the correlation between stiffness and OC and
between stiffness and CrossLaps. P values of 0Æ05 or less were
considered to be statistically significant. SAS software (SAS 9.1,
Cary, NC, USA) was used for the analysis.
Results
Anthropometric, biochemical and bone marker data (mean ± SD)
for homozygous normal subjects (N/N) and individuals heterozy-
gous for the GHRHR mutation (MUT/N) are shown in Table 1.
The statistical analysis did not change when individuals aged more
than 50 years (37%) were excluded. There were no differences in
age or height between groups but weight (P = 0Æ007) and BMI
P = 0Æ001 were lower in MUT/N.
There were no differences in IGF-I or glucose between groups,
but insulin and HOMAIR (P < 0Æ01) were significantly lower in
MUT/N. For the HOMAIR, the mean magnitude of difference was
0Æ23 ± 0Æ11, 95% confidence interval from 0Æ12 to 0Æ448, P = 0Æ03.
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Table 2 shows the data of the general linear model using HOMA IR
as a dependent variable and anova with two factors (sex and
group) adjusted for age and BMI. The model was able to explain
23% of the variability of the HOMAIR, being in the model BMI, the
principal determinant of this variability, with an adjusted R square
of 0Æ134 (explaining 13Æ4% of the HOMAIR variability). The only
other significant covariate was group, with an adjusted R square of
0Æ134 (explaining only 3% of HOMAIR variability). There was no
effect of age, sex and interaction between group and sex in
HOMAIR.
While serum OC did not differ between groups, CrossLaps levels
were significantly lower in the MUT/N group. The regression
model showed no association between weight with OC and Cross-
Laps in MUT/N (R2 = 0Æ00001, P = 0Æ98 and R2 = 0Æ0000001,
P = 0Æ99, respectively) and N/N (R2 = 0Æ00003, P = 0Æ96 and
R2 = 0Æ02, P = 0Æ18, respectively) or BMI with OC and CrossLaps
in MUT/N (R2 = 0Æ02, P = 0Æ3 and R2 = 0Æ00001, P = 0Æ98, respec-
tively) or N/N (R2 = 0Æ02, P = 0Æ28 and R2 = 0Æ02, P = 0Æ19,
respectively). There was no correlation between OC and glucose
(r = 0Æ12; P = 0Æ693), OC and insulin (r = )0Æ05; P = 0Æ673) and
OC and HOMAIR (r = )0Æ06; P = 0Æ603), between stiffness and
OC (r = 0Æ06 P = 0Æ83), or between stiffness and CrossLaps
(r = 0Æ08; P = 0Æ59) when all 140 individuals were analysed as a
whole or when the individual groups were analysed. Similarly,
there was no correlation between age and any bone marker in all
individuals, or when the groups were analysed separately (Fig. 1).
The parameter values obtained by QUS T-Score (N/
N = 0Æ09 ± 1Æ53 vs MUT/N = 0Æ07 ± 1Æ32) and stiffness (N/
N = 96Æ63 ± 23Æ83 vs MUT/N = 96Æ32 ± 19Æ32%) did not differ
significantly between groups.
Discussion
The GH-IGF-I axis plays a pivotal role in maintaining bone health,
and GHD may predispose to loss of bone19 and to fracture.20 Addi-
tionally, previous studies have shown that a mild decline in the
GH/IGF-I axis is associated with bone loss during ageing. Our
results show that heterozygosity for a GHRHR mutation is associ-
ated with reduced body weight, BMI, serum insulin and HOMAIR,
all factors that could potentially influence bone strength. The pres-
ent study confirms data obtained previously when using infrared
interactance, we showed that absolute lean mass was reduced in
MUT/N, while there was significant difference in percentage of fat
mass but a trend of reduction in absolute fat.17 It is necessary to
taken into account a critical period for fat mass development take
place during childhood. Therefore, the trend in reduction in fat
mass and BMI may reflect impairment of preadipocytes differentia-
tion, which have high IGF-I receptor expression.21 Although both
BMI and group are significantly associated with HOMAIR, the
general linear model showed that BMI explains the reduction in
HOMAIR more than the group effect in MUT/N shown in this
protocol with a good power. However, the mechanism responsible
for these alterations remains to be determined; one may hypothe-
size that they reflect a reduction in GH secretion caused by GHRHR
haploinsufficiency, which may not be unveiled by a reduction in
serum IGF-I. To test this hypothesis, it will be necessary to compare
the 24-h GH secretion profile of MUT/N to N/N individuals. The
lack of difference in serum IGF-I between WT/MT and N/N
suggests that these effects in adulthood are not modulated by circu-
lating serum IGF-I, although the expression of IGF-I receptor in
muscle or fat tissue in MUT/N is unknown.
Particularly, the low BMI has been reported to influence the risk
of osteoporosis.22 However, in our study, T-score and absolute
value of stiffness as measured by heel QUS were similar in both
Table 1. Anthropometric data, SDS of serum IGF-I levels (SDS IGF- I),
biochemical and heel quantitative ultrasound (mean ± SD) in 76 normal
homozygous and 64 heterozygous (MUT/N) subjects
N/N MUT/N P
Age (year) 44Æ71 ± 11Æ5 46Æ61 ± 14Æ11 NS
Weight (kg) 65Æ71 ± 14Æ12 59Æ72 ± 11Æ61 0Æ007
Height (m) 1Æ57 ± 0Æ098 1Æ57 ± 1Æ200 NS
BMI (kg/m2) 26Æ32 ± 4Æ91 24Æ02 ± 4Æ43 0Æ001
SDS IGF-I )0Æ73 ± 1Æ36 )0Æ98 ± 1Æ54 NS
Glucose (mmol/l) 5Æ20 ± 0Æ54 5Æ19 ± 0Æ65 NS
Insulin (pmol/l) 28Æ77 ± 19Æ95 19Æ52 ± 17Æ00 0Æ01
HOMAIR 1Æ00 ± 0Æ68 0Æ69 ± 0Æ59 0Æ01
Osteocalcin (lg/l) 23Æ61 ± 11Æ52 25Æ53 ± 11Æ32 NS
CrossLaps (lg/mmol) 350Æ5 ± 280Æ12 220Æ16 ± 150Æ23 0Æ01
T-score 0Æ09 ± 1Æ53 0Æ07 ± 1Æ35 NS
Z-score 0Æ61 ± 1Æ42 0Æ61 ± 1Æ32 NS
Stiffness (%) 96Æ63 ± 23Æ84 93Æ34 ± 19Æ31 NS
Homeostasis model assessment of insulin resistance (HOMAIR) was calcu-
lated by the formula: fasting serum insulin (lU/ml) · fasting plasma
glucose (mmol/l)/22Æ5.
IGF, insulin-like growth factor; SDS, standard deviation scores; NS, not sig-
nificant.
Table 2. General linear model using homeostasis model assessment of
insulin resistance as a dependent variable and anova with two factors (sex
and group) adjusted for age and BMI
Source
Type III
sum of
squares
Degrees of
freedom
Mean
square F Sig.
Partial
g2
Observed
power*
Corrected
model
13Æ82† 5 2Æ76 7Æ90 0Æ0001 0Æ23 0Æ999
Intercept 0Æ97 1 0Æ97 2Æ78 0Æ098 0Æ020 0Æ38
Age 0Æ003 1 0Æ003 0Æ009 0Æ923 0Æ0001 0Æ05
BMI 7Æ26 1 7Æ26 20Æ75 0Æ00001 0Æ134 0Æ995
Group 1Æ53 1 1Æ53 4Æ37 0Æ03 0Æ03 0Æ55
Sex 0Æ93 1 0Æ93 2Æ6 0Æ10 0Æ019 0Æ367
Group*sex 0Æ44 1 0Æ44 1Æ25 0Æ26 0Æ009 0Æ199
Error 46Æ89 134 0Æ35
Total 160Æ87 140
Corrected
total
60Æ73 139
Partial Eta squared = effect dimension; Group*sex: interaction group and
sex.
*Computed using alpha = 0Æ05.
†R2 = 0Æ23 (adjusted R2 = 0Æ199).
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groups, demonstrating that bone quality is not impaired in hetero-
zygous GHRHR individuals. However, while homozygosity for the
mutation leads to decreased bone quality, heterozygosis has no
impact on bone ultrasound parameters. This condition is not
exclusive of GHRHR deficiency. The genetically engineered mouse
knockout for the vitamin D receptor (VDR) shows bone disorder
as well as lean phenotype. On the other hand, VDR heterozygote
male mouse has a lean phenotype but normal bone structure.23
The use of QUS rather than dual-emission X-ray absorptiometry
(DXA) in this study was dictated by logistic reasons. Although the
WHO has objectively defined osteoporosis based on BMD assess-
ment (i.e. T-Score £)2Æ5 standard deviations below normal peak
bone mass), osteoporotic fracture can occur across a wide spectrum
of BMDs, suggesting an important role not only of bone mass, but
also of bone quality. Additionally, in several conditions such as dia-
betes mellitus and obesity, increased bone fragility occurs in spite
of normal or even increased BMD. Heel ultrasound has some
advantages over other more expensive options such as computed
tomography, quantitative peripheral tomography, magnetic reso-
nance and DXA. Particularly, QUS is the only technique suitable
for use in field studies and correlates with both fracture risk and
bone quality.24–28
MUT/N individuals exhibited a predominantly anabolic profile
of biochemical markers of bone remodelling: while serum OC
levels were similar to those of control individuals, the parameter of
bone resorption was significantly decreased in MUT/N patients.
Therefore, it can be hypothesized that the conserved bone forma-
tion associated with lower resorption activity is a mechanism for
the maintenance of bone quality in MUT/N individuals in compar-
ison with the previous MUT/MUT group.16 There are few studies
dedicated to the investigation of BMI effect on bone remodelling
markers. BMI has been shown to have a negative effect in both
types of bone markers, that is formation and resorption with
women after menopause exhibited the strongest negative associa-
tion.29 In the present study, however, this association was not
found.
We did not find any correlation between serum levels of OC and
glucose, insulin and HOMAIR. Lee et al.,
30 and Ferna´ndez-Real
et al.2 have recently demonstrated that bone regulates the insulin/
glucose axis and energy metabolism in mice. Osteoblast cells and
uncarboxylated OC have a pivotal role in this network.31 In paral-
lel, Pitta et al.3 showed that both carboxylated and undercarboxy-
lated OC was significantly correlated with insulin and HOMAIR. In
the BMI range of our patients (25–30 kg/m2), the reference
HOMAIR of Brazilian adult individuals ranges between 0Æ4 and 4Æ3,
with a mean of 1Æ7, and a threshold value for insulin resistance of
2Æ71.32 This value is above our HOMAIR values in both MUT/N
and N/N. Therefore, the low values of both MUT/N and N/N
might have extinguished a possible correlation between OC and
HOMAIR. In addition, recently reduced serum total OC was asso-
ciated with metabolic syndrome in older men as shown by waist
circumference, hyperglycaemia and triglyceride levels. The associa-
tions between serum total OC and these parameters were most
apparent at the levels of total OC below a threshold of 20 lg/l,31
while the mean OC value of our MUT/N individuals was
25Æ5 ± 11Æ32 lg/l. Differently from individuals with metabolic
syndrome, the MUT/N individuals presented lower lean mass,
waist and hip circumferences, and glucose and triglyceride levels
Fig. 1 (a) Spearman correlations between age to
osteocalcin (OC) (r = )0Æ08, P = 0Æ617) and age to
CrossLaps (r = )0Æ06, P = 0Æ761) in control (N/N)
group. (b) Spearman correlations between age to
OC (r = )0Æ31, P = 0Æ342) and age to CrossLaps
(r = )0Æ02, P = 0Æ866) in GHRHR heterozygote
MUT/N group.
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similar to those of N/N.17 These data suggest that only reduced
serum total OC can identify individuals at increased risk of meta-
bolic syndrome.
Our study has some limitations. We did not measure serum
levels of vitamin D, calcium and alkaline phosphatase, but both
groups live in the same environmental condition (equatorial area,
with abundant year-around sunlight exposure) and have similar
diet habit. Additionally, the normal result obtained in bone evalua-
tion suggests no major impairment on vitamin D supply. Another
one is that only one-third of all individuals were older than
50 years. In control individuals, bone loss and decreased IGF-I
production are coincident factors of the ageing process. It will be
important to evaluate whether ageing in MUT/N individuals is
associated with accelerated bone loss by studying a larger number
of older individuals.
In conclusion, the present study shows that a monoallelic muta-
tion in the GHRHR gene does not impact skeletal growth and bone
ultrasonometry parameters in middle-aged individuals. However,
these individuals exhibit a lean phenotype and an advantage in
insulin sensitivity, assessed by homeostasis model assessment of
insulin resistance.
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